The risk or severity of adverse effects can be increased when _ is combined with _ axetil.	0
The risk or severity of bleeding and gastrointestinal bleeding can be increased when _ is combined with _.	1
The risk or severity of adverse effects can be increased when _ is combined with _ zirconium Zr-89.	2
The risk or severity of hypotension can be increased when _ is combined with _.	3
The therapeutic efficacy of _ can be decreased when used in combination with _.	4
The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when _ is combined with _.	5
The risk or severity of bleeding and bruising can be increased when _ is combined with _.	6
_ may increase the neuroexcitatory activities of _.	7
_ may increase the QTc-prolonging activities of _.	8
The risk or severity of liver damage can be increased when _ is combined with _.	9
The risk or severity of myopathy and rhabdomyolysis can be increased when _ is combined with _.	10
_ may decrease the excretion rate of _ undecanoate which could result in a higher serum level.	11
The risk or severity of bleeding and hemorrhage can be increased when Sodium Citrate is combined with _.	12
The risk or severity of QTc prolongation can be increased when _ is combined with _.	13
The metabolism of _ can be increased when combined with _ acetate.	14
The risk or severity of bleeding can be increased when _ is combined with _ ethyl.	15
The risk or severity of bleeding can be increased when _ is combined with Sodium Citrate.	16
The risk or severity of hypoglycemia can be increased when _ is combined with _.	17
The risk or severity of adverse effects can be increased when _ mafodotin is combined with _.	18
The serum concentration of _ can be increased when it is combined with _.	19
The metabolism of _ cypionate can be increased when combined with _.	20
_ may increase the antiplatelet activities of _.	21
The risk or severity of hypertension can be increased when _ is combined with _.	22
The serum concentration of _ acetate can be increased when it is combined with _.	23
_ may increase the hyperkalemic activities of _.	24
The risk or severity of bleeding can be increased when _ is combined with _.	25
_ etexilate may increase the anticoagulant activities of _.	26
The risk or severity of cardiotoxicity can be increased when _ is combined with _.	27
_ may increase the serotonergic activities of _.	28
_ may increase the anticholinergic activities of _.	29
The risk or severity of infection can be increased when _ is combined with _.	30
_ may decrease the excretion rate of _ which could result in a higher serum level.	31
_ may increase the sedative activities of _.	32
The risk or severity of congestive heart failure and hypotension can be increased when _ is combined with _.	33
The risk or severity of bleeding and hemorrhage can be increased when _ is combined with Sodium Citrate.	34
The risk or severity of adverse effects can be increased when _ is combined with Sodium Citrate.	35
The risk or severity of adverse effects can be increased when _ is combined with _.	36
_ may increase the myopathic rhabdomyolysis activities of _.	37
_ may increase the orthostatic hypotensive and hypotensive activities of _.	38
The therapeutic efficacy of Sodium Citrate can be increased when used in combination with _.	39
The serum concentration of the active metabolites of _ can be reduced when _ is used in combination with _ resulting in a loss in efficacy.	40
The risk or severity of hyperkalemia can be increased when _ is combined with _.	41
The risk or severity of Cardiac Arrhythmia can be increased when _ is combined with _.	42
The metabolism of _ can be decreased when combined with _ caproate.	43
_ may increase the hypotensive and vasodilatory activities of _.	44
_ may increase the hypoglycemic activities of _.	45
_ may increase the bradycardic activities of _.	46
_ may increase the tachycardic activities of _.	47
The risk or severity of bleeding can be increased when Sodium Citrate is combined with _.	48
The therapeutic efficacy of Sodium Citrate can be decreased when used in combination with _.	49
The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when _ is combined with _.	50
_ may decrease the excretion rate of _ cypionate which could result in a higher serum level.	51
The risk or severity of adverse effects can be increased when _con-1 is combined with _.	52
The risk or severity of adverse effects can be increased when _-2b is combined with _.	53
The risk or severity of hypotension and CNS depression can be increased when _ is combined with _.	54
_ may increase the excretion rate of _ which could result in a lower serum level and potentially a reduction in efficacy.	55
The risk or severity of hemorrhage can be increased when _ is combined with _.	56
The risk or severity of bleeding and hemorrhage can be increased when _ is combined with _.	57
_ may increase the myelosuppressive activities of _.	58
The risk or severity of respiratory depression can be increased when _ is combined with _.	59
The risk or severity of pulmonary toxicity can be increased when _ is combined with _.	60
The serum concentration of the active metabolites of _ can be increased when _ is used in combination with _.	61
The risk or severity of adverse effects can be increased when _-n1 is combined with _.	62
_ may decrease the antiplatelet activities of _.	63
The excretion of _ can be decreased when combined with _.	64
The serum concentration of _ can be decreased when it is combined with _.	65
_ may increase the neuromuscular blocking activities of _.	66
The risk or severity of angioedema can be increased when _ is combined with _.	67
The protein binding of _ can be decreased when combined with _.	68
_ may increase the arrhythmogenic activities of _.	69
The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when _ is combined with _.	70
The risk or severity of bronchospasm, shortness of breath, and dyspnea can be increased when _ is combined with _.	71
_ may increase the hypotensive activities of _.	72
_ may decrease the antihypertensive activities of _.	73
The risk or severity of methemoglobinemia can be increased when _ is combined with _.	74
The excretion of _ can be increased when combined with _.	75
The therapeutic efficacy of _ can be decreased when used in combination with Sodium Citrate.	76
_ may increase the neurotoxic activities of _.	77
The risk or severity of gastrointestinal bleeding and thrombocytopenia can be increased when _ is combined with _.	78
The risk or severity of hypokalemia can be increased when _ is combined with _.	79
The risk or severity of gastrointestinal bleeding can be increased when Sodium Citrate is combined with _.	80
_ may increase the nephrotoxic activities of _.	81
The metabolism of _ can be increased when combined with _.	82
The risk or severity of adverse effects can be increased when _-n3 is combined with _.	83
_ may decrease the anticoagulant activities of _.	84
The risk or severity of congestive heart failure, bleeding, hypotension, and Tachycardia can be increased when _ is combined with _.	85
The serum concentration of _ propionate can be increased when it is combined with _.	86
The risk or severity of gastrointestinal irritation can be increased when _ is combined with _.	87
_ may increase the hypertensive activities of _.	88
The risk or severity of adverse effects can be increased when _ is combined with _ emtansine.	89
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when _ is combined with _.	90
_ may decrease the sedative and stimulatory activities of _.	91
_ may increase the orthostatic hypotensive activities of _.	92
_ can cause a decrease in the absorption of _ resulting in a reduced serum concentration and potentially a decrease in efficacy.	93
_ may increase the antiplatelet activities of Sodium Citrate.	94
The risk or severity of Tachycardia can be increased when _ is combined with _.	95
The risk or severity of orthostatic hypotension can be increased when _ is combined with _.	96
_ may increase the thrombogenic activities of _.	97
The risk or severity of leukopenia can be increased when _ is combined with _.	98
The risk or severity of adverse effects can be increased when Sodium Citrate is combined with _.	99
_ may increase the immunosuppressive activities of _.	100
The therapeutic efficacy of _ can be increased when used in combination with _.	101
The metabolism of _ benzoate can be increased when combined with _.	102
The risk or severity of constipation can be increased when _ is combined with _.	103
The risk or severity of gastrointestinal bleeding and peptic ulcer can be increased when _ is combined with _.	104
The risk or severity of torsade de pointes and Cardiac Arrhythmia can be increased when _ is combined with _.	105
_ may increase the anticoagulant activities of _.	106
The metabolism of _ enanthate can be increased when combined with _.	107
Sodium Citrate may increase the anticoagulant activities of _.	108
_ may decrease the anticoagulant activities of Sodium Citrate.	109
The risk or severity of myelosuppression can be increased when _ is combined with _.	110
_ may increase the hepatotoxic activities of _.	111
The risk or severity of gastrointestinal bleeding can be increased when _ is combined with _.	112
_ may increase the cardiotoxic activities of _.	113
The risk or severity of CNS depression can be increased when _ is combined with _.	114
The serum concentration of 5-amino-imidazole-4-carboxamide (AIC), an active metabolite of _, can be increased when used in combination with _.	115
The risk or severity of serotonin syndrome can be increased when _ is combined with _.	116
_ may increase the anticoagulant activities of Sodium Citrate.	117
The risk or severity of QTc prolongation can be decreased when _ is combined with _.	118
_ may increase the antihypertensive activities of _.	119
The risk or severity of bradycardia can be increased when _ is combined with _.	120
The risk or severity of neuromuscular blockade can be increased when _ is combined with _.	121
The risk or severity of liver enzyme elevations can be increased when _ is combined with _.	122
The risk or severity of hypercoagulability can be increased when _ is combined with _.	123
The risk or severity of Thrombosis can be increased when _ is combined with _.	124
The risk or severity of serotonin syndrome and seizure can be increased when _ is combined with _.	125
The risk or severity of nephrotoxicity can be increased when _ is combined with _.	126
_ can cause an increase in the absorption of _ resulting in an increased serum concentration and potentially a worsening of adverse effects.	127
The risk or severity of renal failure can be increased when _ is combined with _.	128
The absorption of _ can be decreased when combined with _.	129
The metabolism of _ acetate can be decreased when combined with _.	130
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when _ is combined with _.	131
The risk or severity of adverse effects can be decreased when _ is combined with _.	132
The risk or severity of hemorrhage can be increased when _ is combined with Sodium Citrate.	133
The risk or severity of hypotension, dyspepsia, and headache can be increased when _ is combined with _.	134
The metabolism of _ valerate can be increased when combined with _.	135
The risk or severity of bleeding and bruising can be increased when Sodium Citrate is combined with _.	136
The risk or severity of infection and neutropenia can be increased when _ is combined with _.	137
The risk or severity of orthostatic hypotension and syncope can be increased when _ is combined with _.	138
_ may decrease the hypertensive activities of _.	139
The risk or severity of Tachycardia and drowsiness can be increased when _ is combined with _.	140
The metabolism of (S)-_ can be increased when combined with _.	141
The metabolism of _ can be decreased when combined with _.	142
The risk or severity of neutropenia can be increased when _ is combined with _.	143
_ may increase the central nervous system depressant (CNS depressant) activities of _.	144
_ may decrease effectiveness of _ as a diagnostic agent.	145
